Tumor Biology

, Volume 36, Issue 2, pp 757–767 | Cite as

Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China

  • Yuqian Sun
  • He Huang
  • Jing Chen
  • Jianyong Li
  • Jun Ma
  • Juan Li
  • Yingmin Liang
  • Jianmin Wang
  • Yan Li
  • Kang Yu
  • Jianda Hu
  • Jie Jin
  • Chun Wang
  • Depei Wu
  • Yang Xiao
  • Xiaojun HuangEmail author
Research Article


This stud y examined the epidemiology, risk factors, management, and outcome of invasive fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in China. IFI risk factors were analyzed using univariate analysis and multivariate logistic regression. In total, 4,192 patients receiving 4,889 chemotherapy courses were enrolled [mean age 40.7 years, 58.4 % male, 16.9 % children (<18 years)]. The most common hematological diseases were acute myeloid leukemia (AML, 28.5 %), non-Hodgkin lymphoma (NHL, 26.3 %), and acute lymphoblastic leukemia (ALL, 20.2 %). Severe neutropenia (absolute neutrophil count [ANC] <500/mm3) occurred after one third (1,633/4,889, 33.4 %) of chemotherapy courses. Incidence of proven/probable IFI was 2.1 % per chemotherapy course and higher in patients with myelodysplastic syndrome (MDS, 4.94 %), acute hyperleukocytic leukemia (AHL, 4.76 %), AML (3.83 %), or induction chemotherapy. Risk factors included ANC <500/mm3 [odds ratio (OR) 3.60], AML or MDS (OR 1.97), induction chemotherapy (OR 2.58), previous IFI (OR 3.08), and being male (OR 1.74). Antifungal agents, prescribed in one quarter (1,211/4,889, 24.8 %) of chemotherapy courses, included primary/secondary prophylaxis (n = 827, 16.9 %) and/or treatment (n = 655, 13.4 %; 86.9 % triazoles), which was empirical (84.3 %), pre-emptive (8.6 %), or targeted (7.1 %). Overall mortality following each chemotherapy course (1.5 %) increased in proven/probable (11.7 %) and possible IFI (8.2 %). In summary, IFI was more common in MDS, AHL, AML, or induction chemotherapy, and substantially increased mortality. Neutropenic patients receiving induction chemotherapy for AML or MDS and those with previous IFI were at particular risk. Antifungal prophylaxis showed an independent protective effect but was not commonly used, even in high-risk patients. By contrast, empiric antifungals were widely used.


IFI Chemotherapy Hematological cancer Mortality Antifungal 



The authors would like to thank the patients and investigators at each study site, without whom this study would not have been possible. CAESAR study group investigators not listed as authors were: Yu Ji, Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing; Li Yu and Zhanxiang Liu, Chinese PLA General Hospital (301 Hospital), Beijing; Huisheng Ai and Jianhui Qiao, Chinese PLA 307 Hospital, Beijing; Daobin Zhou and Haiyan Xie, Peking Union Medical College Hospital, Beijing; Hanyun Ren and Mangju Wang, The First Hospital of Peking University, Beijing; Ting Liu and Juan Xu, West China Hospital, Sichuan University, Chengdu; Tingbo Liu, Fujian Medical University Union Hospital, Fuzhou; Fanyi Meng and Guopan Yu, Nanfang Hospital, Nanfang Medical University, Guangzhou; Huo Tan and Runhui Zheng, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou; Xin Du and Chengwei Luo, Guangdong General Hospital, Guangzhou; Waiyi Zou, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou; Jin Zhou and Liming Li, The First Hospital of Harbin Medical University, Harbin; Keyu Liu, Harbin Hematologic Tumor Institution, Harbin; Xiaoyan Zhang, Jiangsu Province Hospital, Nanjing; Jian Ouyang and Yong Xu, Nanjing Drum Tower Hospital, Nanjing; Jun Yang and Yu Cai, The First People’s Hospital of Shanghai, Shanghai; Xianmin Song, Changhai Hospital of the Second Military Medical University, Shanghai; Zhixiang Shen and Ling Wang, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai; Ran Gao, The First Affiliated Hospital of China Medical University, Shengyang; Zhuogang Liu and Ying Yang, The Second Affiliated Hospital of China Medical University, Shengjing Hospital, Shenyang; Yonghua Li, The General Hospital of Guangzhou Military Command of PLA, Guangzhou; Jun Wang, The First Affiliated Hospital of Soochow University, Suzhou; Jianxiang Wang, Mingzhe Han and Guixin Zhang, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences, Tianjin; Zonghong Shao and Chen Tong, General Hospital of Tianjin Medical University, Tianjin; Xudong Hu and Xingzhou Ren, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou; Ping Zou and Yong You, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan; Guohui Li, Tangdu Hospital, Fourth Military Medical University, Xi’an; Hai Bai and Chunbang Wang, The General Hospital of Lanzhou Military Area, Lanzhou; Liansheng Zhang and Lingling Yue, The Second Affiliated Hospital of Lanzhou University, Lanzhou; Yongping Song and Yuewen Fu, Henan Tumour Hospital affiliated to Zhengzhou University, Zhengzhou; Xinghua Chen and Lei Gao, Xinqiao Hospital, The Second Affiliated Hospital of Third Military Medical University, Chongqing; Lin Liu and Li Wang, The First Affiliated Hospital of Chongqing Medical University, Chongqing; Yongmin Tang and Heping Shen, Children’s Hospital of Zhejiang University Medical schoool, Hangzhou; Xia Qin, Shanghai Children’s Medical Center, Shanghai; Liya Ma and Wangzhuo Xie, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou China. This work was supported by Merck Sharp & Dohme China, who sponsored the study. Support for manuscript development was provided by Merck & Co., Inc, USA. The authors accept direct responsibility for this paper and are grateful for the contribution made by Esther Nathanson, MD, and Izabel James, at Watermeadow Medical (supported by Merck & Co., Inc, Whitehouse Station, NJ, USA) in developing a first draft from an agreed outline, collating comments and providing editorial assistance.

Conflicts of interest



  1. 1.
    des Champs-Bro B, Leroy-Cotteau A, Mazingue F, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther. 2011;36:152–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96:748–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–75.PubMedGoogle Scholar
  4. 4.
    Herbrecht R, Caillot D, Cordonnier C, et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother. 2012;67:2731–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Hahn-Ast C, Glasmacher A, Mückter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010;65:761–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Arendrup MC, Boekhout T, Akova M, et al. ESCMID/ECMM joint clinical guideline for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2013. doi: 10.1111/1469-0691.12360.Google Scholar
  7. 7.
    Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18 Suppl 7:53–67.CrossRefPubMedGoogle Scholar
  9. 9.
    Alothman AF, Al-Musawi T, Al-Abdely HM, et al. Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health. 2014;7:6–19.CrossRefPubMedGoogle Scholar
  10. 10.
    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMedGoogle Scholar
  12. 12.
    Song AX, Huang Y, Yang DL, et al. Risk factors and prognosis of invasive fungal infections in patients with hematological diseases. Zhonghua Xue Ye Xue Za Zhi. 2011;32:507–11.PubMedGoogle Scholar
  13. 13.
    Huang BH, Li J, Liu JR, et al. The clinical features and risk factors for invasive fungal infection in multiple myeloma. Zhonghua Nei Ke Za Zhi. 2009;48:1026–30.PubMedGoogle Scholar
  14. 14.
    Zhang CZ, Fung MA, Eisen DB. Disseminated fusariosis presenting as panniculitis-like lesions on the legs of a neutropenic girl with acute lymphoblastic leukemia. Dermatol Online J. 2009;15:5.PubMedGoogle Scholar
  15. 15.
    Zhang P, Jiang EL, Yang DL, et al. Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. Transpl Infect Dis. 2010;12:316–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang ZY, Jiang EL, Zhang P, et al. Invasive fungal infections after allogeneic hematopoietic stem cell transplantation and related risk factors. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:618–22.PubMedGoogle Scholar
  17. 17.
    Xu LP, Ji Y, Liu DH, et al. The prevalence and risk factors of invasive fungal infection in hematopoietic stem cell transplant recipients. Zhonghua Nei Ke Za Zhi. 2007;46:486–9.PubMedGoogle Scholar
  18. 18.
    Ji Y, Xu LP, Huang XJ. Cross-sectional investigation of first-choice of antifungal agents in empirical and preemptive antifungal therapy for patients with hematological malignancies. Zhonghua Xue Ye Xue Za Zhi. 2013;34:473–7.PubMedGoogle Scholar
  19. 19.
    De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Watanabe N, Matsumoto K, Kojima S, et al. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. J Pediatr Hematol Oncol. 2011;33:270–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoenigl M, Zollner-Schwetz I, Sill H, et al. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses. 2011;54:454–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.CrossRefPubMedGoogle Scholar
  23. 23.
    Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:581–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95:644–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother. 2013;68:1660–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Nicolle MC, Bénet T, Thiebaut A, et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica. 2011;96:1685–91.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Muskett H, Shahin J, Eyres G, Harvey S, Rowan K, Harrison D. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15:R287. doi: 10.1186/cc10574.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yang SP, Chen YY, Hsu HS, Wang FD, Chen LY, Fung CP. A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. BMC Infect Dis. 2013;13:10. doi: 10.1186/1471-2334-13-10.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kriengkaukiyiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–91.Google Scholar
  30. 30.
    Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses. 2007;50:302–10.CrossRefPubMedGoogle Scholar
  32. 32.
    Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5–14. doi: 10.1093/jac/dkq437.CrossRefPubMedGoogle Scholar
  33. 33.
    Prevention and Treatment of Cancer-related Infections. National Comprehensive Cancer Network (NCCN) Guidelines. Available at:
  34. 34.
    Wang J, Zhan P, Zhou R, et al. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. Med Oncol. 2010;27:1082–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Shen Y, Huang XJ, Wang JX, et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther. 2013;51:738–45.CrossRefPubMedGoogle Scholar
  36. 36.
    Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yuqian Sun
    • 1
  • He Huang
    • 2
  • Jing Chen
    • 3
  • Jianyong Li
    • 4
  • Jun Ma
    • 5
  • Juan Li
    • 6
  • Yingmin Liang
    • 7
  • Jianmin Wang
    • 8
  • Yan Li
    • 9
  • Kang Yu
    • 10
  • Jianda Hu
    • 11
  • Jie Jin
    • 2
  • Chun Wang
    • 12
  • Depei Wu
    • 13
  • Yang Xiao
    • 14
  • Xiaojun Huang
    • 1
    Email author
  1. 1.Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijingChina
  2. 2.The First Affiliated Hospital of Medical School of Zhejiang UniversityHangzhouChina
  3. 3.Shanghai Children’s Medical CenterShanghaiChina
  4. 4.Jiangsu Province HospitalNanjingChina
  5. 5.Harbin Hematologic Tumor InstitutionHarbinChina
  6. 6.The First Affiliated Hospital of Sun Yat-Sen UniversityGuangzhouChina
  7. 7.Tangdu Hospital, Fourth Military Medical UniversityXi’anChina
  8. 8.Changhai Hospital of the Second Military Medical UniversityShanghaiChina
  9. 9.The First Affiliated Hospital of China Medical UniversityShengyangChina
  10. 10.The First Affiliated Hospital of Wenzhou Medical CollegeWenzhouChina
  11. 11.Fujian Medical University Union HospitalFuzhouChina
  12. 12.The First People’s Hospital of ShanghaiShanghaiChina
  13. 13.The First Affiliated Hospital of Soochow UniversitySuzhouChina
  14. 14.The General Hospital of Guangzhou Military Command of PLAGuangzhouChina

Personalised recommendations